Ovarian Suppression: Early Menopause, Late Effects.
Breast cancer
Hormone receptor positive
Hypoestrogenism
Ovarian function suppression
Pre-menopausal
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
accepted:
11
12
2023
medline:
2
2
2024
pubmed:
2
2
2024
entrez:
2
2
2024
Statut:
aheadofprint
Résumé
Pre-menopausal women diagnosed with hormone receptor (HR) breast cancer are candidates for prolonged hypoestrogenism to improve cancer outcomes. However, the disease benefit eclipses the toxicities associated with ovarian function suppression (OFS), which are often under-reported. Increased risk of mortality from cardiovascular disease, bone disorders, and metabolic disorders is well reported in women with no history of cancer, after surgical oophorectomy or premature ovarian failure. Vasomotor symptoms, urogenital atrophy, weight gain, sexual dysfunction, cognitive decline, and sleep disturbances contribute to the increased non-compliance associated with OFS, especially in younger women. Balancing the toxicities of prolonged OFS with its benefits should be critically analyzed by providers when making recommendations for their patients. Supportive care to manage multi-system toxicities and to counteract the long-term impact on all-cause mortality should be emphasized by every cancer program. Future studies with OFS should incorporate patient outcomes and strategies for symptom management in addition to focusing on improving disease outcomes.
Identifiants
pubmed: 38305992
doi: 10.1007/s11912-023-01491-5
pii: 10.1007/s11912-023-01491-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153–79.
pubmed: 29584099
pmcid: 5518378
Paterson R, Russel MH. Clinical trials in malignant disease. Part II-breast cancer: value of irradiation of the ovaries. J Fac Radiol. 1959;10:130–3.
doi: 10.1016/S0368-2242(59)80037-3
pubmed: 24546197
Heer E, Harper A, Escandor N, Sung H, Mccormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37. https://doi.org/10.1016/S2214-109X(20)30215-1 .
doi: 10.1016/S2214-109X(20)30215-1
pubmed: 32710860
Vaz-Luis I, Francis PA, Di Meglio A, Stearns V. Challenges in adjuvant therapy for premenopausal women diagnosed with luminal breast cancers. Am Soc Clin Oncol Educ Book. 2021;41:1–15. https://doi.org/10.1200/EDBK_320595 .
doi: 10.1200/EDBK_320595
pubmed: 33989019
Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427. https://doi.org/10.1186/s13058-014-0427-5 .
doi: 10.1186/s13058-014-0427-5
pubmed: 25436920
pmcid: 4303229
Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24(36):5769–79. https://doi.org/10.1200/JCO.2006.07.2793 .
doi: 10.1200/JCO.2006.07.2793
pubmed: 17130515
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122–37. https://doi.org/10.1056/NEJMoa1803164 .
doi: 10.1056/NEJMoa1803164
pubmed: 29863451
pmcid: 6193457
Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436–46. https://doi.org/10.1056/NEJMoa1412379 .
doi: 10.1056/NEJMoa1412379
pubmed: 25495490
Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013;22(6):1094–100. https://doi.org/10.1016/j.breast.2013.08.009 .
doi: 10.1016/j.breast.2013.08.009
pubmed: 24095609
Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol. 2013;121(4):709–16. https://doi.org/10.1097/AOG.0b013e3182864350 .
doi: 10.1097/AOG.0b013e3182864350
pubmed: 23635669
pmcid: 4254662
Rocca WA, Grossardt BR, De Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–8. https://doi.org/10.1016/S1470-2045(06)70869-5 .
doi: 10.1016/S1470-2045(06)70869-5
pubmed: 17012044
Gray RG, Bradley R, Braybrooke J, Clarke M, Hills RK, Peto R, et al. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. J Clin Oncol. 2023;41(16_suppl):503–503. https://doi.org/10.1200/JCO.2023.41.16_suppl.503 .
doi: 10.1200/JCO.2023.41.16_suppl.503
Kabirian R, Havas J, Franzoi MA, Coutant C, Tredan O, Levy C, et al. Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): results from the prospective CANTO cohort study. Ann Oncol. 2022;33(7):S1257–S1257. https://doi.org/10.1016/j.annonc.2022.07.1645 .
doi: 10.1016/j.annonc.2022.07.1645
Bellet M, Gray KP, Francis PA, Lang I, Ciruelos E, Lluch A, et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016;34(14):1584–93. https://doi.org/10.1200/JCO.2015.61.2259 .
doi: 10.1200/JCO.2015.61.2259
pubmed: 26729437
pmcid: 4872316
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017;35(27):3113-+. https://doi.org/10.1200/Jco.2016.72.0946 .
doi: 10.1200/Jco.2016.72.0946
pubmed: 28654365
pmcid: 5597253
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014;32(35):3948–58. https://doi.org/10.1200/JCO.2014.55.6993 .
doi: 10.1200/JCO.2014.55.6993
pubmed: 25349302
pmcid: 4251958
Li JW, Liu GY, Ji YJ, Yan X, Pang D, Jiang ZF, et al. Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial. Cancer Manag Res. 2019;11:299–307. https://doi.org/10.2147/CMAR.S183672 .
doi: 10.2147/CMAR.S183672
pubmed: 30643455
Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006;42(7):895–904. https://doi.org/10.1016/j.ejca.2005.12.013 .
doi: 10.1016/j.ejca.2005.12.013
pubmed: 16545560
Kauffman RP, Young C, Castracane VD. Perils of prolonged ovarian suppression and hypoestrogenism in the treatment of breast cancer: is the risk of treatment worse than the risk of recurrence? Mol Cell Endocrinol. 2021;525:111181. https://doi.org/10.1016/j.mce.2021.111181 .
doi: 10.1016/j.mce.2021.111181
pubmed: 33529690
Lehman MN, Coolen LM, Goodman RL. Minireview: kisspeptin/neurokinin B/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion. Endocrinology. 2010;151(8):3479–89. https://doi.org/10.1210/en.2010-0022 .
doi: 10.1210/en.2010-0022
pubmed: 20501670
pmcid: 2940527
Fan Y, Tang R, Prior JC, Chen R. Paradigm shift in pathophysiology of vasomotor symptoms: effects of estradiol withdrawal and progesterone therapy. Drug Discov Today Dis Model. 2020;32:59–69. https://doi.org/10.1016/j.ddmod.2020.11.004 .
doi: 10.1016/j.ddmod.2020.11.004
Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–58. https://doi.org/10.1016/S1470-2045(15)00049-2 .
doi: 10.1016/S1470-2045(15)00049-2
pubmed: 26092816
pmcid: 4562429
Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, De Azambuja E, Vaz-Luis I, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–13. https://doi.org/10.1016/S1470-2045(20)30666-5 .
doi: 10.1016/S1470-2045(20)30666-5
pubmed: 33891888
Glaser RL, York AE, Dimitrakakis C. Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors. J Clin Oncol. 2014;32(26_suppl):109–109. https://doi.org/10.1200/jco.2014.32.26_suppl.109 .
doi: 10.1200/jco.2014.32.26_suppl.109
Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152(2):231–7. https://doi.org/10.1007/s10549-015-3465-5 .
doi: 10.1007/s10549-015-3465-5
pubmed: 26067931
Shams T, et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med. 2014;29(1):204–13.
Leon-Ferre RA, Novotny PJ, Wolfe EG, Faubion SS, Ruddy KJ, Flora D, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a Randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020;4(1):pkz088. https://doi.org/10.1093/jncics/pkz088 .
doi: 10.1093/jncics/pkz088
pubmed: 32337497
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol. 2023;141(4):737–47. https://doi.org/10.1097/AOG.0000000000005114 .
doi: 10.1097/AOG.0000000000005114
pubmed: 36897180
pmcid: 10026946
Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023. https://doi.org/10.1210/clinem/dgad058 .
doi: 10.1210/clinem/dgad058
pubmed: 37978826
pmcid: 10505533
Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239–46. https://doi.org/10.1097/GME.0000000000002138 .
doi: 10.1097/GME.0000000000002138
pubmed: 36720081
pmcid: 9970022
Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–18. https://doi.org/10.1016/S1470-2045(11)70364-3 .
doi: 10.1016/S1470-2045(11)70364-3
pubmed: 22340966
pmcid: 3314999
Jang S, Ko Y, Sasaki Y, Park S, Jo J, Kang NH, et al. Acupuncture as an adjuvant therapy for management of treatment-related symptoms in breast cancer patients: systematic review and meta-analysis (PRISMA-compliant). Medicine (Baltimore). 2020;99(50):e21820. https://doi.org/10.1097/MD.0000000000021820 .
doi: 10.1097/MD.0000000000021820
pubmed: 33327222
Walker EM, Rodriguez AI, Kohn B, Ball RM, Pegg J, Pocock JR, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010;28(4):634–40. https://doi.org/10.1200/JCO.2009.23.5150 .
doi: 10.1200/JCO.2009.23.5150
pubmed: 20038728
Marshall-Mckenna R, Morrison A, Stirling L, Hutchison C, Rice AM, Hewitt C, et al. A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Support Care Cancer. 2016;24(4):1821–9. https://doi.org/10.1007/s00520-015-2967-3 .
doi: 10.1007/s00520-015-2967-3
pubmed: 26446702
Reid RL, Magee B, Trueman J, Hahn PM, Pudwell J. Randomized clinical trial of a handheld cooling device (Menopod(R)) for relief of menopausal vasomotor symptoms. Climacteric. 2015;18(5):743–9. https://doi.org/10.3109/13697137.2015.1042856 .
doi: 10.3109/13697137.2015.1042856
pubmed: 26029989
Composto J, Leichman ES, Luedtke K, Mindell JA. Thermal comfort intervention for hot-flash related insomnia symptoms in perimenopausal and postmenopausal-aged women: an exploratory study. Behav Sleep Med. 2021;19(1):38–47. https://doi.org/10.1080/15402002.2019.1699100 .
doi: 10.1080/15402002.2019.1699100
pubmed: 31801384
Maioli S, Leander K, Nilsson P, Nalvarte I. Estrogen receptors and the aging brain. Essays Biochem. 2021;65(6):913–25. https://doi.org/10.1042/EBC20200162 .
doi: 10.1042/EBC20200162
pubmed: 34623401
pmcid: 8628183
Schwartz MD, Mong JA. Estradiol modulates recovery of REM sleep in a time-of-day-dependent manner. Am J Physiol Regul Integr Comp Physiol. 2013;305(3):R271–80. https://doi.org/10.1152/ajpregu.00474.2012 .
doi: 10.1152/ajpregu.00474.2012
pubmed: 23678032
pmcid: 3743004
Brown, A.M.C. and Gervais, N.J. Role of ovarian hormones in the modulation of sleep in females across the adult lifespan. Endocrinology 2020; 161(9) https://doi.org/10.1210/endocr/bqaa128
Taylor TR, Huntley ED, Makambi K, Sween J, Adams-Campbell LL, Frederick W, et al. Understanding sleep disturbances in African-American breast cancer survivors: a pilot study. Psychooncology. 2012;21(8):896–902. https://doi.org/10.1002/pon.2000 .
doi: 10.1002/pon.2000
pubmed: 21648016
Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26(5):768–77. https://doi.org/10.1200/JCO.2007.14.3248 .
doi: 10.1200/JCO.2007.14.3248
pubmed: 18258985
Yeo SM, Lim JY, Kim SW, Chae BJ, Yu J, Ryu JM, et al. Impact of adjuvant hormone therapy on sleep, physical activity, and quality of life in premenopausal breast cancer: 12-month observational study. J Breast Cancer. 2023;26(2):93–104. https://doi.org/10.4048/jbc.2023.26.e11 .
doi: 10.4048/jbc.2023.26.e11
pubmed: 37051646
pmcid: 10139843
Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol. 2016;34(14):1601–10. https://doi.org/10.1200/JCO.2015.64.8675 .
doi: 10.1200/JCO.2015.64.8675
pubmed: 27022111
pmcid: 4872319
Cho NY, Kim S, Nowakowski S, Shin C, Suh S. Sleep disturbance in women who undergo surgical menopause compared with women who experience natural menopause. Menopause. 2019;26(4):357–64. https://doi.org/10.1097/GME.0000000000001257 .
doi: 10.1097/GME.0000000000001257
pubmed: 30422933
Hickey M, Moss KM, Krejany EO, Wrede CD, Domchek SM, Kirk J, et al. What happens after menopause? (WHAM): a prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2021;162(2):447–53. https://doi.org/10.1016/j.ygyno.2021.05.036 .
doi: 10.1016/j.ygyno.2021.05.036
pubmed: 34116835
Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335–50. https://doi.org/10.1007/s11606-007-0251-z .
doi: 10.1007/s11606-007-0251-z
pubmed: 17619935
pmcid: 2219774
Kripke DF. Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Res. 2016;5:918. https://doi.org/10.12688/f1000research.8729.3 .
doi: 10.12688/f1000research.8729.3
pubmed: 27303633
Wang SH, Chen WS, Tang SE, Lin HC, Peng CK, Chu HT, et al. Benzodiazepines associated with acute respiratory failure in patients with obstructive sleep apnea. Front Pharmacol. 2018;9:1513. https://doi.org/10.3389/fphar.2018.01513 .
doi: 10.3389/fphar.2018.01513
pubmed: 30666205
Ma Y, Hall DL, Ngo LH, Liu Q, Bain PA, Yeh GY. Efficacy of cognitive behavioral therapy for insomnia in breast cancer: a meta-analysis. Sleep Med Rev. 2021;55:101376. https://doi.org/10.1016/j.smrv.2020.101376 .
doi: 10.1016/j.smrv.2020.101376
pubmed: 32987319
Makari-Judson G, Viskochil R, Katz D, Barham R, Mertens WC. Insulin resistance and weight gain in women treated for early stage breast cancer. Breast Cancer Res Treat. 2022;194(2):423–31. https://doi.org/10.1007/s10549-022-06624-1 .
doi: 10.1007/s10549-022-06624-1
pubmed: 35596826
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8.
Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of weight gain during adjuvant endocrine therapy and association of such weight gain with recurrence in long-term breast cancer survivors. Clin Breast Cancer. 2018;18(1):e7–13. https://doi.org/10.1016/j.clbc.2017.11.006 .
doi: 10.1016/j.clbc.2017.11.006
pubmed: 29239836
Teras LR, Patel AV, Wang M, Yaun SS, Anderson K, Brathwaite R, et al. Sustained weight loss and risk of breast cancer in women 50 years and older: a pooled analysis of prospective data. J Natl Cancer Inst. 2020;112(9):929–37. https://doi.org/10.1093/jnci/djz226 .
doi: 10.1093/jnci/djz226
pubmed: 31845728
Bandera EV, Qin B, Lin Y, Zeinomar N, Xu B, Chanumolu D, et al. Association of body mass index, central obesity, and body composition with mortality among black breast cancer survivors. JAMA Oncol. 2021;7(8):1–10. https://doi.org/10.1001/jamaoncol.2021.1499 .
doi: 10.1001/jamaoncol.2021.1499
pubmed: 34086040
pmcid: 8377573
Bui KT, Willson ML, Goel S, Beith J, Goodwin A. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochr Database Syst Rev. 2020;3(3):CD013538. https://doi.org/10.1002/14651858.CD013538 .
doi: 10.1002/14651858.CD013538
Zhang P, Li CZ, Jiao GM, Zhang JJ, Zhao HP, Yan F, et al. Effects of ovarian ablation or suppression in premenopausal breast cancer: a meta-analysis of randomized controlled trials. Eur J Surg Oncol. 2017;43(7):1161–72. https://doi.org/10.1016/j.ejso.2016.11.011 .
doi: 10.1016/j.ejso.2016.11.011
pubmed: 28024943
Juvet LK, Thune I, Elvsaas IKO, Fors EA, Lundgren S, Bertheussen G, et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis. Breast. 2017;33:166–77. https://doi.org/10.1016/j.breast.2017.04.003 .
doi: 10.1016/j.breast.2017.04.003
pubmed: 28415013
Phillips KA, Regan MM, Ribi K, Francis PA, Puglisi F, Bellet M, et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016;114(9):956–64. https://doi.org/10.1038/bjc.2016.71 .
doi: 10.1038/bjc.2016.71
pubmed: 27092785
pmcid: 4984913
Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET. Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis. Psychoneuroendocrinology. 2019;106:9–19. https://doi.org/10.1016/j.psyneuen.2019.03.013 .
doi: 10.1016/j.psyneuen.2019.03.013
pubmed: 30928686
Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, De Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–83. https://doi.org/10.1212/01.wnl.0000276984.19542.e6 .
doi: 10.1212/01.wnl.0000276984.19542.e6
pubmed: 17761551
Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM. Association of premenopausal bilateral oophorectomy with cognitive performance and risk of mild cognitive impairment. JAMA Netw Open. 2021;4(11):e2131448. https://doi.org/10.1001/jamanetworkopen.2021.31448 .
doi: 10.1001/jamanetworkopen.2021.31448
pubmed: 34762113
pmcid: 8586907
Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135(1):54–70. https://doi.org/10.1016/j.pharmthera.2012.03.007 .
doi: 10.1016/j.pharmthera.2012.03.007
pubmed: 22484805
pmcid: 5688223
Jordan, J.H., D’agostino, R.B., Jr., Ansley, K., Douglas, E., Melin, S., Sorscher, S. et al. Myocardial function in premenopausal women treated with ovarian function suppression and an aromatase inhibitor. JNCI Cancer Spectr 2021; 5(4) https://doi.org/10.1093/jncics/pkab071
Chou YS, Wang CC, Hsu LF, Chuang PH, Cheng CF, Li NH, et al. Gonadotropin-releasing hormone agonist treatment and ischemic heart disease among female patients with breast cancer: a cohort study. Cancer Med. 2023;12(5):5536–44. https://doi.org/10.1002/cam4.5390 .
doi: 10.1002/cam4.5390
pubmed: 36305849
Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol. 2021;28:100355. https://doi.org/10.1016/j.jbo.2021.100355 .
doi: 10.1016/j.jbo.2021.100355
pubmed: 33948427
pmcid: 8080519
Stumpf U, Kostev K, Kyvernitakis J, Bocker W, Hadji P. Incidence of fractures in young women with breast cancer - a retrospective cohort study. J Bone Oncol. 2019;18:100254. https://doi.org/10.1016/j.jbo.2019.100254 .
doi: 10.1016/j.jbo.2019.100254
pubmed: 31440445
pmcid: 6698802
Go J, Park S, Kim KS, Kang MC, Ihn MH, Yun S, et al. Risk of osteoporosis and fracture in long-term breast cancer survivors. Korean J Clin Oncol. 2020;16(1):39–45. https://doi.org/10.14216/kjco.20007 .
doi: 10.14216/kjco.20007
pubmed: 36945309
pmcid: 9942721
Leslie WD, Morin SN, Lix LM, Niraula S, Mccloskey EV, Johansson H, et al. Fracture risk in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study. Oncologist. 2019;24(11):1432–8. https://doi.org/10.1634/theoncologist.2019-0149 .
doi: 10.1634/theoncologist.2019-0149
pubmed: 31292269
pmcid: 6853130
Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916–46. https://doi.org/10.1200/JCO.19.01696 .
doi: 10.1200/JCO.19.01696
pubmed: 31532726
Leslie WD, Morin SN, Lix LM, Niraula S, Mccloskey EV, Johansson H, et al. Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a Registry-Based Cohort study. J Bone Miner Res. 2019;34(8):1428–35. https://doi.org/10.1002/jbmr.3726 .
doi: 10.1002/jbmr.3726
pubmed: 31069862
Ishikawa T. Differences between zoledronic acid and denosumab for breast cancer treatment. J Bone Miner Metab. 2023;41(3):301–6. https://doi.org/10.1007/s00774-023-01408-z .
doi: 10.1007/s00774-023-01408-z
pubmed: 36879056
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1650–63. https://doi.org/10.1016/j.annonc.2020.07.019 .
doi: 10.1016/j.annonc.2020.07.019
pubmed: 32801018
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313–20. https://doi.org/10.1093/annonc/mdu544 .
doi: 10.1093/annonc/mdu544
pubmed: 25403582
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60–72. https://doi.org/10.1016/S1470-2045(19)30687-4 .
doi: 10.1016/S1470-2045(19)30687-4
pubmed: 31806543
Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(3):339–51. https://doi.org/10.1016/S1470-2045(18)30862-3 .
doi: 10.1016/S1470-2045(18)30862-3
pubmed: 30795951
Hanson A, G.J., Ormerod C, Katze N, Teteh D, Ericson M. Living beyond breast cancer; Chapman University. The changing informational needs of young women affected by breast cancer: a national needs assessment. In 2022.
Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492–511. https://doi.org/10.1200/JCO.2017.75.8995 .
doi: 10.1200/JCO.2017.75.8995
pubmed: 29227723
Carter J, Baser RE, Goldfrank DJ, Seidel B, Milli L, Stabile C, et al. A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. Support Care Cancer. 2021;29(1):311–22. https://doi.org/10.1007/s00520-020-05472-3 .
doi: 10.1007/s00520-020-05472-3
pubmed: 32358778
Goldfarb SB, et al. Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. J Clin Oncol. 2023;41(16_suppl):12015.
The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstetr Gynecol 2016; 127(3): E93-E96.
Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause-the J North Am Menopause Soc. 2018;25(6):596–608. https://doi.org/10.1097/Gme.0000000000001121 .
doi: 10.1097/Gme.0000000000001121
Pederson HJ, Faubion SS, Pruthi S, Goldfarb S. RE: systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2023;115(2):220–1. https://doi.org/10.1093/jnci/djac211 .
doi: 10.1093/jnci/djac211
pubmed: 36409007
Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361–70. https://doi.org/10.1097/GME.0000000000001463 .
doi: 10.1097/GME.0000000000001463
pubmed: 31794498
Archer DF, Constantine GD, Simon JA, Kushner H, Mayer P, Bernick B, et al. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause-the J North Am Menopause Soc. 2017;24(5):510–6. https://doi.org/10.1097/Gme.0000000000000790 .
doi: 10.1097/Gme.0000000000000790
Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, et al. Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance). Support Care Cancer. 2018;26(4):1335–43. https://doi.org/10.1007/s00520-017-3960-9 .
doi: 10.1007/s00520-017-3960-9
pubmed: 29164377
Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2011;126(2):443–51. https://doi.org/10.1007/s10549-010-1332-y .
doi: 10.1007/s10549-010-1332-y
pubmed: 21221770
Lee YJ, Wu ZY, Kim HJ, Lee JW, Chung I, Kim J, et al. Change in estradiol levels among premenopausal patients with breast cancer treated using leuprolide acetate 11.25 milligrams 3-month depot and tamoxifen. J Breast Cancer. 2020;23(5):553–9. https://doi.org/10.4048/jbc.2020.23.e57 .
doi: 10.4048/jbc.2020.23.e57
pubmed: 33154830
pmcid: 7604376